Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

Michael_garic Jan. 16 at 11:32 PM

$AUTL I've read the CEO's Q4 preannouncement. He talked about the increasing patient numbers, but he is projecting 135M on the high end of revenue. If we use 450K discounted price per treatment that equates to 300 patients. There are 63 centers open, that would be about 5 patients per center per year. That just sounds extremely low to me unless they are intentionally trying for a slow ramp. Maybe this is because they are finding it difficult to get to positive gross margins with the existing process and need to optimize or get to the Cellares solution??? Anyone else have more info on this?

1 · Reply

01xxxxx Jan. 16 at 10:27 PM

$AUTL if they can stop or even cure ms, then they will dramatically change peoples lives all around the world. So far there is nothing that can do this.

1 · Reply

gandolf63 Jan. 16 at 9:20 PM

$AUTL at some point as the company gets closer to the finish line, BioNtech is gonna say fuck it we are buying it. I think they are just waiting to see the result, by end of year

1 · Reply

medinapj Jan. 16 at 8:26 PM

$AUTL What a crappy end to the week 🤕

0 · Reply

Joe_90_ Jan. 16 at 7:55 PM

$AUTL they've got this pinned today, wait until the call options expire today, it'll rally on Tuesday, tuesday will be a green day in the markets, patience 😀

1 · Reply

Night_Owl_Biotech Jan. 15 at 7:45 PM

Change in share prices for all comm'l-stage oncology focused bios since last Friday (before the start of JPM). Note the share prices are intra-day as of Thursday 1/15/26 for entertainment purposes. The XBI is up slightly so far for the week yet only 4 of the 24 (market caps over $300MM) are trading meaningfully higher. $IBRX is the big winner after reporting impressive data in lung cancer. Just remember last year at JP Morgan the IBRX CEO said money was no problem because they can always issue more stock. $SNDX is unchanged. Many SNDX loyalists were hoping Incyte would announce their acquisition at the start of the week. One SNDX analyst pulled their FY2029 estimate at the start of the week but it appears it was re-added. SNDX FY29 estimates are higher than last Friday. SNDX is our #1 holding which is why we post so often. $NUVB is a loser after reporting Q425 product sales that appears to have disappointed. $AUTL missed & guided FY26 below ests We don't see any new $VSTM news. Any input?

0 · Reply

Biotechs5454 Jan. 15 at 7:13 PM

$AUTL Think we need a few more bearish posts please 🙏

1 · Reply

MedHS55 Jan. 15 at 6:45 PM

$AUTL The algos are at work again. Tons of trade at $1.4250

0 · Reply

chelfen Jan. 15 at 5:13 PM

$AUTL with lower cost and higher production capacity they will take this step and revenues will 10-fold

0 · Reply

JessTaylor22 Jan. 15 at 4:02 PM

$AUTL “NHS England estimates that around 50 patients a year may benefit, but [Dr.] Tholouli told the BBC she believed it could be more, and predicted it would eventually be used as a first-line treatment instead of stem cell transplantation.”

1 · Reply

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Jan 6, 2026, 9:00 AM EST - 10 days ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Jan 6, 2026, 9:00 AM EST - 10 days ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

$Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025$

Dec 8, 2025, 4:05 PM EST - 5 weeks ago

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 8, 2025, 8:35 AM EST - 5 weeks ago

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 1, 2025, 7:00 AM EST - 6 weeks ago

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Nov 25, 2025, 12:37 PM EST - 7 weeks ago

Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

$NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹$

Nov 25, 2025, 4:00 AM EST - 7 weeks ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Nov 14, 2025, 10:28 AM EST - 2 months ago

Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline

Nov 13, 2025, 4:05 PM EST - 2 months ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 3:11 PM EST - 2 months ago

Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:00 AM EST - 2 months ago

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 3, 2025, 9:05 AM EST - 2 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 30, 2025, 7:00 AM EDT - 2 months ago

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 27, 2025, 7:00 AM EDT - 2 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 20, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Oct 15, 2025, 4:05 PM EDT - 3 months ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 8:05 AM EDT - 4 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 5:26 PM EDT - 5 months ago

Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable

Aug 12, 2025, 4:37 PM EDT - 5 months ago

Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 5 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 6 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jun 12, 2025, 2:00 AM EDT - 7 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 6, 2025, 11:09 AM EDT - 8 months ago

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

May 29, 2025, 4:05 PM EDT - 8 months ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 8 months ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 20, 2025, 5:47 AM EDT - 8 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC CAPR CLPT EDIT NTLA VANI VERV

May 14, 2025, 9:30 AM EDT - 8 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 11, 2025, 4:22 AM EDT - 8 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 9 months ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 9 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 9 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 9 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 10 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 10 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 11:55 AM EDT - 10 months ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 10 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 11 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 4, 2025, 10:21 AM EST - 11 months ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Jan 17, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 12:16 AM EST - 1 year ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 12, 2024, 2:57 PM EST - 1 year ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Sep 6, 2024, 2:12 PM EDT - 1 year ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Aug 10, 2024, 12:05 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Michael_garic Jan. 16 at 11:32 PM

1 · Reply

01xxxxx Jan. 16 at 10:27 PM

$AUTL if they can stop or even cure ms, then they will dramatically change peoples lives all around the world. So far there is nothing that can do this.

1 · Reply

gandolf63 Jan. 16 at 9:20 PM

$AUTL at some point as the company gets closer to the finish line, BioNtech is gonna say fuck it we are buying it. I think they are just waiting to see the result, by end of year

1 · Reply

medinapj Jan. 16 at 8:26 PM

$AUTL What a crappy end to the week 🤕

0 · Reply

Joe_90_ Jan. 16 at 7:55 PM

$AUTL they've got this pinned today, wait until the call options expire today, it'll rally on Tuesday, tuesday will be a green day in the markets, patience 😀

1 · Reply

Night_Owl_Biotech Jan. 15 at 7:45 PM

0 · Reply

Biotechs5454 Jan. 15 at 7:13 PM

$AUTL Think we need a few more bearish posts please 🙏

1 · Reply

MedHS55 Jan. 15 at 6:45 PM

$AUTL The algos are at work again. Tons of trade at $1.4250

0 · Reply

chelfen Jan. 15 at 5:13 PM

$AUTL with lower cost and higher production capacity they will take this step and revenues will 10-fold

0 · Reply

JessTaylor22 Jan. 15 at 4:02 PM

1 · Reply

gandolf63 Jan. 15 at 1:29 AM

$AUTL

0 · Reply

Bearbull_Baggins Jan. 15 at 1:12 AM

$AUTL I bought into this when it dropped in november, and used it to successfully practice trading it upwards in 20 cent increments until it got to 2, where i stopped buying (luckily) and expected a natural pullback to 1.60-1.70. This stock follows the fib levels and has predictable entries and exits on the upswing. Good stock for a beginner trader like me to learn from. Once this new dump finds its bottom, I will go at it again trading swings in my cash account. But, i will also enter an actual long position in my IRA, which is currently being transferred from my old 401k and should be available just in time for a 1.20 entry that i can easily forget about and not touch for the rest of the year.

0 · Reply

1GreenDay99RedDays Jan. 14 at 5:43 PM

$AUTL destroyed my March calls, im done with the market, all rigged

2 · Reply

1GreenDay99RedDays Jan. 14 at 5:10 PM

$AUTL

0 · Reply

Biotechs5454 Jan. 14 at 3:59 PM

$AUTL I look forward to the “why didn’t I buy when it was manipulated down to $1.35” posts soon 👍👍👍👊👊👊

1 · Reply

TricksterT Jan. 14 at 3:01 PM

$AUTL shouldn’t go below $0 but we will see if it can find support there.

1 · Reply

gandolf63 Jan. 14 at 12:37 PM

$AUTL I am willing to bet institutions added, and new institutions bought this fear the last couple days

1 · Reply

Biotechs5454 Jan. 14 at 12:09 PM

$AUTL I know many are wringing their hands and I get it but not me. We’re back down close to where I started buying in ($1.20s) but it’s part of the game. My reasons for buying have not changed. I’m much less worried about dilution given what I believe is conservative cash runway projections and conservative revenue numbers. Lupus will be big IMHO. All good here. ✅

0 · Reply

Mancunian Jan. 14 at 10:55 AM

$AUTL https://www.bbc.co.uk/news/articles/c62r56zzzq4o.amp

2 · Reply

Mancunian Jan. 14 at 10:05 AM

$AUTL The first patient in the UK to be treated with Aucatzyl on the NHS was announced this morning..,.

0 · Reply

Michael_garic Jan. 13 at 11:50 PM

$AUTL Warren Buffet said only buy a stock that you want to hold for 10 years. Kind of sums up where we are at. I'm going on year 3. This company is curing the uncurable and expanding their reach to cure more uncurables. I have to commend the management team for their focus on this long-term goal and not enriching their stock options. I only say to the folks in for a quick buck, sell and go somewhere else... maybe AI ! The rest of us "baggers" as they call us can look forward to a nice long-term reward.

0 · Reply

Axchange08 Jan. 13 at 11:20 PM

$AUTL calm down people. Shorts want you to panic. I do services for one of the people in the company. They are working hard to get this company expose through the world. This company is going to have big big news. I’ve placed all bets on this company. Just sit back and let it grow.

2 · Reply

Market Cap	383.25M
Revenue (ttm)	10.12M
Net Income (ttm)	-220.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,180.43%
Debt to Equity Ratio	0.00

Volume	1,908,300
Avg Vol	3,185,224
Day's Range	N/A - N/A
Shares Out	266.14M
Stochastic %K	5%
Beta	2.01
Analysts	Strong Sell
Price Target	$9.34